Oscar Health Shares Plummets 8.18% on $300M Volume Ranking 353rd Despite 2025 Sales Guidance and Hy-Vee Partnership as Q2 Revenue and Earnings Miss Estimates

Oscar Health (OSCR) fell 8.18% on August 20, with a trading volume of $0.30 billion, ranking 353rd among stocks that day. The decline occurred despite the company reaffirming its 2025 sales guidance of $12 billion–$12.2 billion and announcing a partnership with Hy-Vee to launch a new employer health insurance plan. The collaboration will debut in Des Moines, Iowa, targeting 400,000 employees via the individual marketplace starting January 1, 2026, leveraging cost-saving ICHRA structures for businesses and employees.

Second-quarter revenue rose to $2.86 billion from $2.2 billion year-over-year but fell short of the $2.91 billion estimate. The growth was driven by higher membership, though the company reported a loss of 89 cents per share, exceeding the 86-cent consensus. A medical loss ratio of 91.1% for Q2 2025, up from 79.0% in the prior year, highlighted increased costs due to higher average market morbidity and risk adjustment transfers.

The broader health insurance sector saw improved sentiment as high-profile investors showed interest in industry peers. However, Oscar’s stock performance lagged behind, reflecting mixed signals from its financial results and forward guidance. The Hy-Vee partnership, while strategically significant, remains unproven in its market impact ahead of 2026.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The total profit grew steadily over the past year, with a few fluctuations. As of the latest data, the strategy's profit reached $2,385.14.